Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences will release DAYBREAK Phase 3 topline results for wet AMD tomorrow.

What the company is saying

Kodiak Sciences (NASDAQ:KOD) is announcing that it will report topline results from its DAYBREAK Phase 3 study, which evaluates Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for wet age-related macular degeneration, on September 28, 2026. The company is hosting a webcast at 8:30 AM Eastern Time to present these results, with a replay available for a limited time. The announcement frames its pipeline as robust, highlighting three late-stage clinical programs and describing Zenkuda as having a 'BLA-ready profile' in multiple retinal indications. Kodiak emphasizes that Zenkuda and KSI-501 target the $15 billion anti-VEGF market, underscoring the commercial potential. The company also references KSI-101, which is in two BLA-facing Phase 3 studies for macular edema secondary to inflammation, with topline data expected in December 2026 and 2Q 2027. The tone is confident and forward-looking, focusing on imminent data and large market opportunity, but does not provide any financial or clinical outcome details in this release.

What the data suggests

The announcement confirms that Kodiak Sciences will disclose topline results from the DAYBREAK Phase 3 trial for Zenkuda and KSI-501 in wet AMD on September 28, 2026. It states the company has three late-stage clinical programs and that Zenkuda and KSI-501 are positioned to address the $15 billion anti-VEGF market. KSI-101 is in two Phase 3 studies for MESI, with topline data expected in December 2026 and 2Q 2027. The only quantified figure is the $15 billion market size; no enrollment numbers, efficacy data, or regulatory submission dates are provided. The claim that Zenkuda is 'BLA-ready' is not substantiated with supporting data or regulatory milestones. The webcast timing and replay availability are operational details, not value inflection points. Overall, the data points to a company on the cusp of a near-term clinical readout, but with no disclosed results or financials, the actual impact remains unquantified.

Analysis

The announcement is upbeat, emphasizing imminent topline results from a Phase 3 study and highlighting the company's late-stage clinical pipeline. However, the majority of claims are forward-looking, including expectations for future data readouts and references to targeting a large ($15 billion) market. No clinical results, regulatory milestones (such as BLA submission or approval), or financial metrics are disclosed. The language around 'BLA-ready profile' and market targeting inflates the perceived progress, but without topline data or regulatory filings, these remain aspirational. The webcast and data readout are scheduled for the next day, so some benefits are near-term, but most commercial and regulatory outcomes are still pending. There is no mention of capital outlay or immediate earnings impact, so capital intensity is not flagged.

Risk flags

• ●There is no clinical efficacy or safety data disclosed for Zenkuda or KSI-501, so the actual likelihood of regulatory success and commercial adoption is unknown; topline results could materially alter the investment case.
• ●The reference to a $15 billion anti-VEGF market highlights commercial potential but does not address competition, pricing, or the company's ability to capture market share; market access risk remains high.
• ●Statements such as 'BLA-ready profile' are not backed by regulatory filings or approvals, introducing uncertainty around the true readiness of the pipeline for commercialization.
• ●Future milestones for KSI-101 are long-dated, with topline data not expected until December 2026 and 2Q 2027, which delays potential value realization and increases the risk of interim setbacks or changes in the competitive landscape.

Bottom line

Kodiak Sciences is about to release topline results from its pivotal DAYBREAK Phase 3 trial in wet AMD, with a webcast scheduled for September 28, 2026. The company positions its late-stage pipeline as targeting the large $15 billion anti-VEGF market, but provides no efficacy, safety, or regulatory submission data in this announcement. The imminent data readout is a key inflection point, but until results are disclosed, there is no basis to assess the likelihood of regulatory approval or commercial success. The claims of 'BLA-ready' status and market opportunity are aspirational without supporting evidence. Investors should focus on the actual DAYBREAK results when released, as these will determine whether Kodiak's lead assets can advance toward approval and commercialization. The most important takeaway is that the investment case hinges on the quality of data to be revealed tomorrow.

Announcement summary

(NASDAQ:KOD) Kodiak Sciences Inc. announced it will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda™ (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026. The company will host a webcast on that date at 8:30 AM Eastern Time, accessible via the Events and Presentations page on Kodiak's website, with an archived replay available for a limited time. Kodiak Sciences is a pre-commercial retina-focused biotechnology company developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion, and wet AMD. KSI-501 (tabirafusp alfa tedromer) is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026. Topline data for Pivotal Analysis 2 (PEAK+PINNACLE) are expected in 2Q 2027. Kodiak®, Kodiak Sciences®, ABC®, ABC Platform™, Zenkuda™, VETi™, and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Disagree with this article?